openPR Logo
Press release

Rising Prevalence of Epilepsy Is the Key Driver of the Anticonsultants Drug Market

08-14-2017 12:50 PM CET | Health & Medicine

Press release from: Transparency Market Research

Anticonvulsants Drug Market

Anticonvulsants Drug Market

The first line of treatment in pain management usually involves the use of pharmaceuticals from various therapeutic classes such as antidepressants, opioids, NSAIDs, anticonvulsants, anesthetics, and other non-narcotic analgesics. Anticonvulsants, also known as antiepileptic drugs, were developed primarily for the treatment of epileptic seizures. However, leading anticonvulsant drugs such as Lyrica (pregabalin) and Neurontin (gabapentin) have also been approved for the management of various pain indications including fibromyalgia, migraine and neuropathic pain. These approvals are responsible for the increasing importance of anticonvulsants in the management of various pain indications. The overall market for anticonvulsants is highly genericized; however, the market for anticonvulsants for pain management application is dominated by Lyrica, the only branded pharmaceutical among the currently marketed drugs.

Of the major anticonvulsant drugs currently marketed, Lyrica (pregabalin), Neurontin (gabapentin), Topamax (topiramate), Depakote (divalproex), and Carbatrol/Tegretol (carbamazepine) are indicated for management of various types of pain. In 2012, Lyrica registered sales of US$ 5,111 Mn, of which 74% constituted revenue from its pain management indication. Since all the other molecules are generic and have negligible contribution in the pain management application, the market will be driven and dominated by the sales of existing blockbuster drug Lyrica, which constituted 73.4% share of the total market in 2011. The drug was initially set to lose its patent exclusivity in 2015, which would have negatively impacted the market rendering it completely generic. However, Pfizer has obtained market exclusivity for the drug and its use in pain management through to 2018, and is therefore expected to maintain its leadership position.

This report gives readers a comprehensive overview of the Anticonvulsants Drug Market: http://www.transparencymarketresearch.com/anticonvulsants-drug-market.html

Rising prevalence of epilepsy is the key driver of the anticonsultants drug market. Anticonvulsants drug is not only consumed in case of epileptic seizures, but also for pain management in migraine, and fibromyalgia. This boosts the anticonvulsants drug market. Availability of alternative options for pain management acts as a major restraint of the market. Other pain management methods include the use of medical devices such as analgesic pumps and minimally invasive procedures such as denervation or rhizotomy. Pain management implants and devices such as neuromodulators are gaining market acceptance among medical professionals, while acupuncture and acupressure are world-renowned pain relief techniques along with physiotherapy that people adopt. Other devices included in pain relief are transcutaneous electrical nerve stimulation (TENS) that delivers mild shocks to nerves in order to block pain messages to the brain. Hence, competition in the market from other improved pain management methods, devices, and other drugs can also hamper the anticonvulsants drug market. The anticonvulsants drug market has been segmented based on therapeutic class, disease indication, formulation, distribution channel, and region.

Get accurate market forecast and analysis on the Anticonvulsants Drug Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22973

In terms of region, the anticonvulsants drug market has been classified into Asia Pacific, Europe, Middle East & Africa, North America, and Latin America. Key players in the anticonvulsant drug market are Abbott Laboratories, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., Valeant Pharmaceuticals International, Inc., Sanofi, UCB, Shire plc., and Astrazeneca plc.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

Contact us:

Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Rising Prevalence of Epilepsy Is the Key Driver of the Anticonsultants Drug Market here

News-ID: 667977 • Views: 132

More Releases from Transparency Market Research

High Nutritional Content Fuelling Demand For Yogurt Market
Rising awareness about the benefits of yogurt over curd is propelling the demand for yogurt among consumers Yogurt has lower sugar and fat content, making it preferable for health conscious customers. Besides, manufacturers are boosting the nutrition value by adding minerals, vitamins, and fiber in the product. For example, Arla foods, a food manufacturing company, has recently introduced fiber-rich yogurt. The yogurt has high protein content, adequate amount of
Increasing Inclination Towards Healthy Lifestyle To Propel Protein Supplements M …
According to a new report by Transparency Market Research (TMR), a leading market intelligence firm, the global protein supplements market is witnessing a tremendous rise in its valuation, thanks to the increased focus of consumers towards acquiring a healthy lifestyle. With the presence of a large number of players, such as GlaxoSmithKline Plc, Amway Corp., ABH Pharma Inc., Vitacost.com Inc., and Nu Skin Enterprises Inc., the competitive landscape in the
Ginger Market is expected to reach a valuation of US$4.18 bn by the end of 2022
The global reach and acceptance for spices, especially for ginger have been increasing in recent years, presenting promising growth opportunities for large-scale manufacturers and processors of the spice that also promises vast health benefits, observes Transparency Market Research in a recent report. The global ginger market has multiple players, owing to which the vendor landscape is fragmented and is competitive in nature. Read report Overview- https://www.transparencymarketresearch.com/ginger-market.html The dominant players in the global
Feather Meal Market: Import-Export, Industry Chain Structure and Development Opp …
A recent study published by Transparency Market Research on the feather meal market includes global industry analysis and opportunity assessment for 2020-2030. Revenue generated from the global feather meal market was valued at US$ 359.5 Mn in 2020, which is estimated to rise at a CAGR of 8.6%, to reach ~US$ 820 Mn by 2030. Obtain Report Details @ https://www.transparencymarketresearch.com/feather-meal-market.html global feather meal market Nutritive Value of Feather Meal to Influence Feather

All 5 Releases


More Releases for Anticonvulsants

Anticonvulsants Market Therapeutic Survey Reviews, Analysis 2025
The report titled “Anticonvulsants Market” report will be very useful to get a stronger and effective business outlook. It provides an in-depth analysis of different attributes of industries such as trends, SWOT analysis, policies, and clients operating in several regions. The qualitative and quantitative analysis techniques have been used by analysts to provide accurate and applicable data to the readers, business owners and industry experts. The Anticonvulsants market was valued at
Generic and branded anticonvulsants are restraining the growth of novel therapie …
Anticonvulsants, also commonly known as antiepileptic drugs or antiseizure drugs are a diverse group of pharmacology agents used in the treatment of epileptic seizures. Epilepsy is a chronic disorder resulting in repeated and unprovoked seizures. Epileptic seizures are commonly referred as convulsions. Anticonvulsants are mainly used for treatment of epileptic seizures. Epileptic seizures are caused by disturbance in the electrical activity of the brain. In addition, anticonvulsants are also used
Epileptic Anticonvulsants Market Size, Growth, Trends and 2020 Forecast Report
According to the WHO, nearly 80% of epilepsy patients are found in developing regions. However, developed regions are dominant in the global epileptic anticonvulsants market. Currently, North America dominates the epileptic anticonvulsants market, followed by Europe. Highly developed healthcare infrastructure, high level of awareness, high healthcare spending on epilepsy and related treatments, along with availability of skilled professionals to treat epilepsy are driving the North America and Europe epileptic anticonvulsants
Anticonvulsants for Neuropathic Pain Market unprovoked by 2025
Global Anticonvulsants for Neuropathic Pain Market: Snapshot Neuropathic pain, which refers to kind of chronic pain resulting from an injury to or disease of the central or peripheral nervous system, remains a therapeutic challenge to clinicians as it does not respond well to conventional pain therapies. Although the clinical knowledge regarding the pathogenesis of the condition has significantly increased over the past few decades, the actual mode of action of most
Anticonvulsants for Neuropathic Pain Market Business Strategy & Forecast by 2025
Global Anticonvulsants for Neuropathic Pain Market: Snapshot Neuropathic pain, which refers to kind of chronic pain resulting from an injury to or disease of the central or peripheral nervous system, remains a therapeutic challenge to clinicians as it does not respond well to conventional pain therapies. Although the clinical knowledge regarding the pathogenesis of the condition has significantly increased over the past few decades, the actual mode of action of most
Anticonvulsants Drug Market - Significant Growth During 2025
The first line of treatment in pain management usually involves the use of pharmaceuticals from various therapeutic classes such as antidepressants, opioids, NSAIDs, anticonvulsants, anesthetics, and other non-narcotic analgesics. Anticonvulsants, also known as antiepileptic drugs, were developed primarily for the treatment of epileptic seizures. However, leading anticonvulsant drugs such as Lyrica (pregabalin) and Neurontin (gabapentin) have also been approved for the management of various pain indications including fibromyalgia, migraine and